Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II-III triple-negative breast cancer

• Үндсэн зохиолчид: O. O. Gordeeva (Зохиогч), I. V. Kolyadina (Зохиогч), L. G. Zhukova (Зохиогч), I. P. Ganshina (Зохиогч), G. V. Vyshinskaya (Зохиогч), M. A. Kazantseva (Зохиогч), M. V. Sukhova (Зохиогч), O. E. Ryabishina (Зохиогч), E. V. Lubennikova (Зохиогч), D. A. Filonenko (Зохиогч), E. I. Chichikov (Зохиогч), I. N. Polushkina (Зохиогч), E. I. Borisova (Зохиогч), A. N. Lud (Зохиогч), A. A. Meshcheryakov (Зохиогч)
• Формат: Ном
• Хэвлэсэн: ABV-press, 2020-11-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background. Treatment results for the patients with stage II-III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II-III TN BC in...